Keywords: Mersana Therapeutics, Endo Pharmaceuticals, Antibody-drug conjugates, License deal
Mersana inks ADC deal with Endo Pharma
Article | 08 March 2012
Privately-held Mersana Therapeutics has joined the antibody-drug conjugate space, announcing its first ADC deal with fellow USA-based Endo Pharmaceuticals (Nasdaq: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
